Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1716641 | 1.00 | MAPT (0.52) | MAPTKDM4EAPAF1POLBRECQL | |
| Tryptophan SCHEMBL1716928 | 0.86 | KDM4E (0.74) | MAPTKDM4EAPAF1POLBRECQL | |
| SCHEMBL8407071 | 0.81 | ECE1 (0.55) | MAPTKDM4EAPAF1POLBRECQL | |
| SCHEMBL27028793 | 0.80 | DHPS (0.49) | MAPTKDM4EKMT2AMEN1LMNA | |
| SCHEMBL25571556 | 0.80 | GPR84 (0.50) | MAPTKDM4EL3MBTL1STING1KMT2A | |
| SCHEMBL18642525 | 0.80 | HTR6 (0.39) | — | |
| SCHEMBL461014 | 0.80 | CYP2A6 (0.43) | STING1NR4A2 | |
| SCHEMBL22582341 | 0.79 | STING1 (0.45) | MAPTKDM4EAPAF1POLBRECQL | |
| SCHEMBL27765284 | 0.79 | PBRM1 (0.48) | MAPTKDM4EAPAF1POLBRECQL | |
| SCHEMBL28309358 | 0.78 | KDM4E (0.52) | KDM4EKMT2AMEN1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | claimed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | claimed |
| US-6743373-B1 | REAGENT BASED ON ENANTIOPURE AMINO ACID IN WHICH AMINO GROUP CARRIES ACTIVATING GROUP TO FORM ACTIVE PRECURSOR OF ISOCYANATE GROUP AND CARBOXYL GROUP IS SUBSTITUTED; SEPARATION OF ENANTIOMERS HAVING FREE FUNCTIONAL GROUP | SOLVAY (SOCIETE ANONYME) (BE) | 2004-06-01 | — | — | US | claimed |
| WO-2009146885-A2 | LIPIDATED ANTIBACTERIAL PEPTIDES | SPIDERBIOTECH S.R.L. (IT) | 2009-12-10 | — | — | WO | disclosed |
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | disclosed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
| US-6743373-B1 | REAGENT BASED ON ENANTIOPURE AMINO ACID IN WHICH AMINO GROUP CARRIES ACTIVATING GROUP TO FORM ACTIVE PRECURSOR OF ISOCYANATE GROUP AND CARBOXYL GROUP IS SUBSTITUTED; SEPARATION OF ENANTIOMERS HAVING FREE FUNCTIONAL GROUP | SOLVAY (SOCIETE ANONYME) (BE) | 2004-06-01 | — | — | US | disclosed |
| EP-1046627-B1 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (BE) | 2004-02-11 | — | — | EP | disclosed |
| EP-1046627-A2 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (Société Anonyme) (BE) | 2000-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | DNPEP, DAO, ANPEP | MAPT 3874/4885KDM4E 4407/4885APAF1 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.